Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025JAMA Oncology

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJeffrey A. MeyerhardtTTTyler S. TwomblyLPLevi Pederson

Discussion

Loading...

Member takes

Overview

Post hoc analysis shows ctDNA predicts survival outcomes in stage III colon cancer, suggesting adjuvant celecoxib improves prognosis.

Key Points

  • To investigate the predictive value of postoperative circulating tumor DNA for survival outcomes in patients with stage III colon cancer treated with celecoxib.
  • Post hoc analysis of phase 3 clinical trial assessing adjuvant celecoxib vs placebo.
  • Patients had ctDNA analysis performed using a 16-plex-PCR next-generation sequencing assay.
  • Survival outcomes were measured as disease-free survival and overall survival.
  • Among 940 patients, 18.4% were ctDNA positive with worse disease-free survival and overall survival.
  • Celecoxib improved disease-free survival and overall survival in ctDNA positive patients compared to placebo.
  • No survival benefit of celecoxib was observed in ctDNA negative patients.

Cite This Study

Meyerhardt et al. (2025) studied this question.

synapsesocial.com/papers/693624ce4fa91c937236cdb5https://doi.org/10.1001/jamaoncol.2025.5144
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Physical activity and molecular residual disease (MRD) in stage III colon cancer: Findings from CALGB (Alliance)/SWOG 80702.2026
  2. 2Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147)2026 · 5 citations
  3. 3A phase 2 trial of TAS-102 with or without celecoxib in ctDNA-defined minimal residual disease (MRD) in colorectal cancer after completion of adjuvant chemotherapy.2026
  4. 4Disease-free survival (DFS) and time to recurrence (TTR) with circulating tumor (ct) DNA–based decision for adjuvant treatment in colon cancer stage II (CIRCULATE): An AIO (KRK-0217)/ABCSG trial.2026 · 3 citations
  5. 5Chemotherapy for patients with circulating tumour DNA positive, stage II colon cancer (CIRCULATE) – an AIO / ABCSG trial2026 · 4 citations